|
|
|
| Correlation Analysis between Levels of Homocysteine Apolipoprotein A/Apolipoprotein B and Coagulation Indexes in Patients with Chronic Obstructive Pulmonary Disease |
| ZHAO Xuefeng, HAN Jingxu, YUE Hongyun, et al |
| Shijiazhuang People's Hospital, Hebei Shijiazhuang 050000, China |
|
|
|
|
Abstract Objective: To analyze the correlation between level of serum homocysteine (Hcy), apolipoprotein A1 (Apo A1)/apolipoprotein B100 (Apo B100) and blood coagulation indexes in patients with chronic obstructive pulmonary disease (COPD). Methods: The 188 COPD patients admitted to our hospital from Jan 2017 to Dec 2019 were divided into venous thromboembolism (VTE) group (n=92) and non-VTE group (n=96), and the general information of the two groups were compared. Other items of the two groups were compared too, including serum Hcy, Apo A1, Apo B100, Apo A1/Apo B100 levels and coagulation indexes such as activated partial thromboplastin time (APTT), fibrinogen (FIB), prothrombin time (PT), plasma viscosity (PV), D-dimer (DD) and antithrombin III (AT-III) activity. Then correlation analysis between serum Hcy, Apo A1, Apo B100, Apo A1/Apo B100 levels and coagulation indexes of COPD patients were performed. Results: The serum levels of Hcy, Apo B100, FIB, PV and DD in the VTE group were significantly higher than those in the non-VTE group (P<0.05 or P<0.01). The serum levels of Apo A1, Apo A1/Apo B100 and AT-III in the VTE group was significantly lower than those in the non-VTE group (P<0.05 or P<0.01). The levels of Hcy and Apo B100 in the serum of patients with COPD are significantly positively correlated with FIB, PV, and DD and other coagulation indicators (P<0.001), and significantly negatively correlated with AT-III (P<0.001); while Apo A1 and Apo A1/Apo B100 level is significantly negatively correlated with FIB, PV, DD and other coagulation indicators (P<0.001), and there is a significant positive correlation with AT-III (P<0.001). Conclusion: Serum Hcy, Apo A1, Apo B100, Apo A1/Apo B100 levels in COPD patients are correlated with the occurrence of VTE. Clinical monitoring of serum Hcy, Apo A1 and Apo B100 levels is of great value in evaluating the occurrence of VTE in COPD patients.
|
|
|
|
|
|
[1] 林展增.中国慢性阻塞性肺疾病流行病学研究进展[J].河北北方学院学报(自然科学版),2020,36(8):49~51,56.
[2] Dong W,Zhu Y,Du Y,et al.Association between features of COPD and risk of venous thromboembolism[J].Clin Respir J,2019,13(8):499~504.
[3] Chrapko M,Skwarzynski A,Karakuta W,et al.The role of apolipoprotein (a) in pathogenesis and clinical course of deep venous thrombosis[J].Pol Przegl Chir,2015,86(11):518~522.
[4] Borvik T,Brekkan SK,Enga K,et al.COPD and risk of venous thromboembolism and mortality in a general population[J].Eur Respir,2016,47(2):473~481.
[5] Bolaman Z,Kadikoylu G,Ozgel N,et al.Effects of atorvastatin on coagulation parameters and homocysteine in patients with primary hypercholesterolemia[J].Natl Med Assoc,2006,98(8):1273~1277.
[6] Zang RS,Zhang H,Xu Y,et al.Serum C-reactive protein,fibrinogen and D-dimer in patients with progressive cerebral infarction[J].Transl Neurosci,2016,7(1):84~88.
[7] Cukic V,Baljic R.The most common detected risk and etiologic factors of pulmonary thromboembolism[J].Mater Sociomed,2012,24(4):223~226.
[8] Parra ES,Panzoldo NB,Zago VH,et al.HDL size is more accurate than HDL cholesterol to predict carotid subclinical atherosclerosis in individuals classified as low cardiovascular risk[J].PLoS One,2014,9(12):e114212.
[9] Patel VI,Patel KP,Makadia MG,et al.Levels of apolipoprotein A1,B100 and lipoprotein (a) in controlled and uncontrolled diabetic patients and in non-diabetic Healthy People[J].Clin Diagn Res,2017,11(2):BC01~BC05.
[10] Lentini A,Fornengo P,Bosco G,et al.Cryptogenic cerebral infarction in a young patient with very high lipoprotein(a) serum level as the only risk factor[J].Neurol Sci,2007,28(1):42~44. |
|
|
|
2021, Vol. 27 
